News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Senior Research Executives from Boehringer Ingelheim and The Garvan Institute to Present at Pharmaxis Investor Research Briefing
Pharmaceutical research company Pharmaxis (ASX: PXS) advises that it will host an investor research briefing on Tuesday, 20 November from 10am to 12.00pm (AEDT) that will feature presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event will also provide an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program currently completing phase 1 trials and extended toxicity studies.
This is a unique opportunity to hear directly from the Pharmaxis executive research team along with the perspectives of a committed pharmaceutical partner and a leading medical research institute.
Attendance at this event is by invitation only. A live webcast will be accessible to all investors via the homepage of the Pharmaxis website at www.pharmaxis.com.au and will be available for replay after the event.